Phase III trials in oncology

Siegfried Seeber and Ada H Braun

Survival data from phase III trials can be very misleading because patients are not offered the best follow-up therapy argue Siegfried Seeber and Ada Braun in CancerWorld’s new Forum section. Emma Mason canvassed clinical trial leaders, and presents their responses in the Debate section that follows.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.